

K132362

**510(k) SUMMARY**  
**WECK® EFX™ Endo Fascial Closure System**

**A. Name, Address, Phone and Fax Number of Applicant**

Teleflex Medical, Incorporated  
2917 Weck Drive  
Research Triangle Park, NC 27709 USA  
Phone: 919-361-4071  
Fax: 919-433-4996

**B. Contact Person**

Natalie Hichak  
Regulatory Affairs Specialist

Lorraine DeLong  
Manager RA/QE Surgical

OCT 08 2013

**C. Date Prepared**

July 16, 2013

**D. Device Name**

Trade Name: WECK® EFX™ Endo Fascial Closure System

Common Name: Endoscopic tissue approximation device

Classification Name: Endoscope and accessories

**E. Device Description**

Laparoscopic ports are used to establish a port of entry into the abdominal cavity and gain access to the surgical site. Ports are positioned into patients during minimally invasive surgical procedures by trained surgeons in order to provide a pathway for the insertion and removal of surgical devices and removal of specimens. Following the laparoscopic procedure the injury to the abdominal wall defects at the site of the port entry puncture must be repaired and often entails suturing to prevent future complications and particularly herniation. The WECK® EFX™ Endo Fascial Closure System is designed to maintain pneumoperitoneum and facilitate placement and withdrawal of suture loops to perform these repairs.

**F. Indications for Use**

The WECK® EFX™ Endo Fascial Closure System has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites.

**G. Contraindications**

Do not use where laparoscopic techniques are generally contraindicated

**H. Substantial Equivalence**

The proposed WECK® EFX™ Endo Fascial Closure System is substantially equivalent to the predicate devices:

Predicate Device	Manufacturer	510(k) No.	Date Cleared
Axiom Fascial Closure System	Axiom Technology Partners	K103412	December 30, 2010

**I. Comparison To Predicate Devices**

The proposed WECK® EFX™ Endo Fascial Closure System has the same technology, indications for use and functional characteristics as the predicate system. This submission is notification to the agency of the transfer in ownership of the 510(k) K103412 from Axiom Technology Partners LLC to Teleflex Medical Incorporated and to update material and dimensional modifications incorporated subsequent to the clearance of 510(k) K103412 and prior to the transfer of ownership to Teleflex Medical Inc.

**J. Materials**

All patient contacting materials are in compliance with ISO10993-1.

**K. Technological Characteristics**

A comparison of the technological characteristics of the proposed WECK® EFX™ Endo Fascial Closure System and the predicate has been performed. The results of this comparison demonstrate that the WECK® EFX™ Endo Fascial Closure System is equivalent to the marketed predicate devices in performance characteristics.

**L. Performance Data**

The bench testing has been performed to verify that the performance of the proposed WECK® EFX™ Endo Fascial Closure System is substantially equivalent to the

predicate device. The proposed material and dimensional modification was tested according to the scheme and specifications summarized below.

<b>Performance Data Results Summary</b>		
<b>Response Type</b>	<b>Test Specification</b>	<b>Result</b>
Qualitative	Material Verification	<b>PASS</b> Materials were found to meet pre-established specifications.
Qualitative	Visual Inspection for Defects and Cleanliness	<b>PASS</b> All devices passed the inspections for defects and cleanliness.
Quantitative	Dimensional Inspection	<b>PASS</b> Dimensions were found to meet pre-established specifications.
Qualitative and Quantitative	Mechanical Inspection	<b>PASS</b> Function of the device was verified against pre-established specifications.
Qualitative and Quantitative	Suture Retention	<b>PASS</b> Function of the device was verified against pre-established specifications.
Qualitative and Quantitative	Destructive Testing of Failure Modes	<b>PASS</b> The device exceeded the maximum working load of the pre-established specifications.

#### **L. Conclusion**

Based upon the comparative test results, the proposed WECK® EFX™ Endo Fascial Closure System is substantially equivalent in performance to the predicate devices cleared to market via 510(k) K103412. The modifications made to the proposed WECK® EFX™ Endo Fascial Closure System do not introduce any new issues of safety and effectiveness.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - W066-G609  
Silver Spring, MD 20993-0002

Teleflex Medical, Incorporated  
Ms. Natalie Hichak  
Regulatory Affairs Specialist  
2917 Weck Drive  
Research Triangle Park, North Carolina 27709

October 8, 2013

Re: K132362

Trade/Device Name: WECK<sup>36</sup> EFX<sup>TM</sup> Endo Fascial Closure System  
Regulation Number: 21 CFR 876.1500  
Regulation Name: Endoscope and Accessories  
Regulatory Class: Class II  
Product Codes: OCW, GCJ, HCF  
Dated: July 29, 2013  
Received: July 30, 2013

Dear Natalie Hichak,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Page 2 – Ms. Natalie Hichak

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Mark N. Melkerson -S**

Mark N. Melkerson  
Acting Director  
Division of Surgical Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

Page 1 of 1

**510(k) Number:** K132362

**Device Name:** WECK® EFX™ Endo Fascial Closure System

### Indications for Use:

The WECK® EFX™ Endo Fascial Closure System has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites.

**Prescription Use XX**  
(Part 21 CFR 801 Subpart D)

AND/OR

**Over-the-counter use** \_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Jiyoung Dang -S